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ABSTRACT
In Latin America, the causative agent of kala-azar is the intracellular protozoan Leishmania 
infantum. Most cases in South America are reported in Brazil. Worldwide, it mainly affects 
Bangladesh, Ethiopia, India, South Sudan and Sudan. Despite the high morbidity and lethality 
of kala-azar, most infections are asymptomatic. However, a small portion of patients evolves 
with recurrence of kala-azar becoming symptomatic even after all available drug treatments. 
Kala-azar is not a formal indication for splenectomy in adults. Splenectomy is recommended 
as a saving measure, when kala-azar is associated with symptomatic hypersplenism and 
for drug-resistant cases. In the study, we report two cases of kala-azar with splenomegaly 
that presented several hospitalizations due to the recurrence of the kala-azar, in addition to 
hospitalizations for normalizing the blood count. After splenectomy, kala-azar cases and the 
effects of hypersplenism are cured. Thus, splenectomy should be seen as a surgical treatment 
option with a curative purpose in patients with recurrent kala-azar, in whom the possibilities 
of drug therapy have been exhausted and even so they progressed with hypersplenism and 
clinical repercussions.
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INTRODUCTION
In Latin America, the causative agent of kala-azar is the intracellular protozoan 
Leishmania infantum. Most cases in South America are reported in Brazil1. Worldwide, 
in addition to Brazil, kala-azar affects Bangladesh, Ethiopia, India, South Sudan 
and Sudan2. Leishmania infantum parasite multiply within the sand fly Lutzomyia 
longipalpis, during a period from 8 to 20 d, and, in humans, has an incubation period 
between 2 and 6 months1. Despite the high morbidity and lethality of kala-azar, most 
infections by Leishmania infantum in humans are asymptomatic2. Individuals with low 
socioeconomic conditions and immune deficiencies are in general more susceptible 
and develop clinical signs3. Typical kala-azar manifestations include fever, weight 
loss, hepatomegaly, splenomegaly, and pancytopenia resulting from the replication of 
Leishmania amastigotes in macrophages, mainly in the liver, spleen, and bone marrow, 
causing serious injuries and ultimately death4. In the absence of treatment, death occurs 
within a few months after the onset of symptoms5.The treatment of immunocompetent 
patients is very efficient. It is composed of pentavalent antimonials that have been 
replaced by the liposomal amphotericin B or are associated with paramomycin or 
miltefosine, the latter for oral use6. Kala-azar is not a formal indication for splenectomy 
in adults, but splenectomyis recommended as a saving measure, when kala-azar is 
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The male patient was born on June 26, 1986, in 
Paulistana municipality, Piaui State. He was hospitalized at 
the Natan Portella Institute of Tropical Diseases (IDTNP) 
on seven occasions between the years 2009 and 2011, with 
a consistent diagnosis of kala-azar confirmed by laboratory 
examination and tests including the finding of parasite 
amastigotes in bone marrow smears. The patient received 
all the recommended treatments, including the pentavalent 
antimony (glucantime, 20 mg of Sb + 5 kg/d for 30 d in 
first hospitalization), liposomal amphotericin B (for 14 d at 
a dose of 3 mg/kg/d, in three subsequent hospitalizations) 
and pentamidine in the last hospitalization before surgery 
(4 mg/kg/d every other d, for a total of 15 doses), with only 
transient symptomatic improvement followed by recurrence. 
He had a negative HIV serological test. During the other 
two hospitalizations, the patient presented with anemia and 
was transfused twice with packed red blood cells. After 
the all the possibilities of treatment with medications were 
exhausted and the patient maintained a pancytopenia profile 
on the blood count due to hypersplenism, splenectomy 
was recommended. In January 2012, he was hospitalized 
for the surgical procedure. His clinical examination 
revealed mucocutaneous pallor (2 + / 4 +), fever (38.5 °C), 
dehydration (2 + / 4 +), distended abdomen with mild 
pain on deep palpation and splenomegaly (8 cm below 
the left costal margin). Laboratory tests detected anemia, 
leukopenia, hypergammaglobulinemia and high levels of 
ESR (erythrocyte sedimentation rate) and CRP (C-reactive 
protein). On May 2, 2012 splenectomy was carried out and 
the patient was discharged 5 d after surgery. The first 24 h 
of the patient’s postoperative period were held in the ICU 
(Intensive Care Unit) and due to bleeding during surgery, 
the patient received three packed red blood cell transfusions, 
evolving with stable hemoglobin and hematocrit values. 
The spleen measurements were 25 x 17 x 9 cm, weighing 
1860 g. The histopathological study confirmed the presence 
of Leishmania parasites in the surgical specimen. The 
patient was referred to the IDTNP, where he underwent a 
new course of amphotericin B and was discharged on the 
8th day of hospitalization. He remained asymptomatic, with 
improvement observed in laboratory parameters no further 
relapse of leishmaniasis and has been followed-up at the 
outpatient clinic for more than seven years after the surgery. 
Unfortunately we have no images of this patient.
Case 2
The male patient was born on June 6, 1960, in Acaua 
municipality, Piaui State, was a married and was diagnosed 
with kala-azar in January 2014 and had a negative serology 
to HIV. Since then, he evolved with recurrent pancytopenia, 
persistent splenomegaly and a history of five previous 
hospitalizations at the IDTNP for the kala-azar treatment. 
After unsuccessful attempts with all the existing drug 
treatments against kala-azar, such as pentavalent antimony 
(glucantime, 20 mg of Sb + 5 kg/d for 30 d at first 
hospitalization) and liposomal amphotericin B (for 14 d 
at a dose of 3 mg/kg/d, in three hospitalizations), and in 
the face of an evolution with hypersplenism, clinical and 
laboratory repercussions, the patient was admitted in July 
2015 to undergo a splenectomy, and at that time, on the 
physical examination, he presented with a palpable spleen 
at 12 cm from the left costal margin. In the preoperative 
period, an ultrasound of the abdomen was performed 
showing an enlarged spleen extending to the left iliac fossa. 
CBC with Hb 8.7 g/dL; Ht 27.9%; leukocytes 1,090/µL 
and 155,000/µL platelets. He underwent splenectomy on 
August 04, 2015, progressing uneventfully in the intra and 
postoperative periods. The surgical specimen measured 
19.5 x 14.5 x 6 cm and weighed 1,066g (Figures 1 and 2). 
The histopathological study confirmed the presence of 
Leihmania parasites within the splenic parenchyma. He also 
Figure 1 - Spleen: visceral surface (patient of the Case 2).
Figure 2 - Spleen: diaphragmatic surface (patient of the Case 2).
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had 7 d of liposomal amphotericin B during hospitalization. 
In the outpatient follow-up, cholelithiasis was identified, 
which became symptomatic and the patient underwent, 
a video cholecystectomy surgery on November 03, 2017, 
performed by the same team of the splenectomy, also 
evolving without complications. Nowadays, he has been 
followed-up at the outpatient clinic, for more than 4 years 
after the surgery, remaining asymptomatic, without further 
hospitalizations due to kala-azar or medications, and with 
a normal hematological profile.
DISCUSSION 
The spleen behaves as a reservoir of Leishmania 
parasites in the human body and some studies have 
demonstrated a decreased action of anti-leishmania drugs on 
parasites10,14,15. It is part of the natural evolution of kala-azar 
to cause hypersplenism and consequent severe pancytopenia 
which, if left untreated, undoubtedly leads to death. The two 
studied patients, despite attempts of treatment with current 
drugs, evolved with recurrent kala-azar. 
In order to define what is recurrent kala-azar, it is 
necessary to introduce two definitions: persistent kala-azar, 
when the patient has more than 6 months of signs and 
symptoms of the disease after the end of the initial specific 
treatment (liposomal amphotericin B for 14 d at a dose of 
3 mg/kg/d, or an alternative medication) with the presence 
of parasites in the bone marrow; and relapsing kala-azar, 
when the patients who became asymptomatic, had 
recurrences 6 months after the initial diagnosis. Recurrent 
kala-azar occurs when the patients fall into persistent or 
recurrent kala-azar, or both. The patients in the study were 
classified as persistent and recurrent.
Splenectomy can be considered the treatment of choice 
for a number of hematological diseases, including idiopathic 
thrombocytopenic purpura, thrombotic thrombocytopenic 
purpura and hereditary spherocytosis11,12,16. There is 
also indication to perform splenectomy in patients with 
complications of the schistosomiasis infection in addition 
to trauma, splenic abscesses, neoplasia and in patients who 
do not respond to specific drug therapy for kala-azar8-13. 
The latter was the indication for both reported patients. In 
all of these indications, with the exception of emergency 
surgeries, prior vaccination against encapsulated germs is 
necessary at least two weeks before the procedure17. This 
measure was adopted in the studied patients. 
Many studies have shown that splenectomy, although 
not free of complications, is relatively safe: morbidity 
can reach 8% and long-term post-surgical mortality 
4.5%. Among the complications, hematomas, subphrenic 
abscesses, venous thromboembolism, pneumonia and 
fulminant sepsis after splenectomy, are the most cited18,19. 
In a study published in 2010, Thomsen et al.20 warned of an 
increased risk of developing thrombotic events (pulmonary 
thromboembolism and/or deep venous thrombosis) when 
compared to patients undergoing appendectomy and the 
general population. The first patient to be operated was 
younger, but had a larger spleen; remained during the 
first 24 h of the postoperative period in the ICU due to the 
intraoperative blood loss caused by technical difficulties. 
He received three packed red blood cell transfusions and 
was discharged from the ICU on the following day. The 
second patient, 55 years-old on the day of the surgery, 
evolved with no incidents in the trans and postoperative 
periods. Both patients remained asymptomatic, maintaining 
the kala-azar healed status, the first patient for over 7 years 
and the second one for 4 years.
CONCLUSION
Splenectomy should be seen as a surgical treatment 
option with a curative purpose for patients with recurrent 
kala-azar, in whom the possibilities of drug therapy have 
been exhausted and who develop hypersplenism with 
clinical repercussions.
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